MK 571
CAS: 115104-28-4
Ref. TM-T7841
| 1mg | 45.00 € | ||
| 5mg | 88.00 € | ||
| 10mg | 124.00 € | ||
| 25mg | 244.00 € | ||
| 50mg | 361.00 € | ||
| 100mg | 534.00 € | ||
| 500mg | 1,174.00 € | ||
| 1ml*10 (DMSO) | 110.00 € |
Estimated delivery in United States, on Friday 17 May 2024
Product Information
Name:
MK 571
Synonyms:
- L660711, L-660711, MK-571
- 3-[({3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}{[3-(dimethylamino)-3-oxopropyl]sulfanyl}methyl)sulfanyl]propanoic acid
- 3-[[[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propanoic Acid Sodium Salt
- 3-[[[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propanoic acid
- 3-{[(R)-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}{[3-(dimethylamino)-3-oxopropyl]sulfanyl}methyl]sulfanyl}propanoic acid
- L 660711
- L 660711, Sodium Salt
- Mk-571
- Mk-571 Na
- Mk-571 Sodium Salt
- See more synonyms
- Mk-571, Na Salt
- Propanoic acid, 3-[[[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-
- Propanoic acid, 3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-, (E)-
- sodium 3-[({3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}{[3-(dimethylamino)-3-oxopropyl]sulfanyl}methyl)sulfanyl]propanoate
CAS:
Description:
MK 571 (L660711) is an orally active antagonist of CysLT1 receptor.
Brand:
Targetmol
Long term storage:
Notes:
Chemical properties
Molecular weight:
515.09
Formula:
C26H27ClN2O3S2
Purity:
99.57%
Color/Form:
Solid
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TM-T7841 MK 571
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
